<DOC>
	<DOCNO>NCT03030430</DOCNO>
	<brief_summary>The purpose study establish PK similarity treatment BAT1706 comparators .</brief_summary>
	<brief_title>Study Bevacizumab ( BAT1706 ) Comparators Healthy Subjects</brief_title>
	<detailed_description>This Phase I , randomize , double-blind , single-dose , 3-arm parallel group study compare PK , evaluate safety , tolerability immunogenicity , BAT1706 , EU-Avastin US-Avastin single IV infusion healthy adult male subject . A total 129 healthy male subject meet required entry criterion randomly assign one three treatment group 1:1:1 ratio receive single IV infusion either BAT1706 , EU-Avastin US-Avastin . A total 117 evaluable subject require . Initially , subject administer study drug stagger group ; first group comprise 3 subject , second group 6 subject third group 9 subject . Within group subject randomize ensure equal number subject receive three treatment . There least 48 hour administration study drug group . Prior administration study drug next group , safety tolerability finding precede group review Principal Investigator . The next group dose provide serious unexpected drug-related safety issue . Each subject require remain clinical center 48 hour dose safety evaluation . After first 3 group evaluate , Principal Investigator decide whether proceed continuous enrolment accord clinical center capability .</detailed_description>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>1 . Adult male age 18 50 year inclusive body weight 65 100kg . 2 . Subjects healthy determine prestudy medical history , physical examination , vital sign 12 ECG . 3 . Subjects whose clinical laboratory test result normal , outside reference range judge clinical relevant . 1 . Have history and/or current clinically significant gastrointestinal , renal , hepatic , cardiovascular , haematological , pulmonary , neurologic , metabolic , psychiatric allergic disease exclude mild asymptomatic seasonal allergy . 2 . Subject psychiatric disorder consider unsuitable inclusion investigator . 3 . History current clinically significant , exclude mild asymptomatic seasonal allergy , hypersensitivity allergic reaction include know suspected drug hypersensitivity component study drug formulation comparable drug . 4 . Any biological drug within 3 month monoclonal antibody within 9 month study drug administration . 5 . Intake herbal remedy within 14 day prior study drug administration . 6 . History alcohol abuse positive alcohol test screen admission clinical center . 7 . Any person : employee Principal Investigator , clinical center , Clinical Research Organization ( CRO ) Sponsor ; relative employee clinical center , Investigators , CRO Sponsor .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>